IP Library › Granted Patent US 10,004,781
Granted Patent B2
US 10,004,781 · App. 15/000,093 · Granted Jun 26, 2018

Prescription of intravenous medication for blocking heroin or morphine intoxication path and using thereof

Inventor: En-Che Cheng (Kaohsiung, TW)
A61K38/1709A61K9/0019A61K31/375A61K31/407A61K31/4015A61K31/4164A61K31/439A61K31/4515A61K31/51A61K31/553A61K31/5513A61K31/714A61K35/30A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,781
App. No.
15/000,093
Granted
Jun 26, 2018
Kind
B2
Abstract

A prescription of intravenous medication and its treatment method block heroin or morphine intoxication. The prescription of intravenous infusion includes Cerebrolysin, Piracetam, Cimetidine, Scopolamine Butylbromide, Nefopam, B.C Complex, Vitamin B1, Ascorbic Acid, Ketorolac, Guronsan, Hyoscine Butylbromide and Sukerin. The prescription activates a patient's liver and circulatory system to block drug intoxication. The treatment method for blocking drugs includes an acute withdrawal part, with the prescription of intravenous infusion injected and with the timing of drug administration and the safe dosage controlled according to clinical symptoms. An appropriate amount of a supplementary medicine such as Haloperidol is added, and the processes of detoxication, relieving symptoms, suppressing restlessness, and sobering are conducted to block acute withdrawal symptoms of an acute withdrawal addict quickly and successfully.

Claims (26)

1. An intravenous infusion composition for blocking heroin or morphine intoxication, comprising a plurality of ingredients consisting of Cerebrolysin, Piracetam, Cimetidine, Scopolamine Butylbromide, Nefopam, B.C Complex, Vitamin B1, Ascorbic Acid, Ketorolac, Guronsan, Hyoscine Butylbromide, and Sukerin.

2. The intravenous infusion composition according to claim 1 , wherein each ingredient occupies 3˜13% of a dosage.

3. A method for blocking heroin or morphine intoxication comprising administering the intravenous infusion composition according to claim 2 , further including the administration of an an acute withdrawal part wherein said part is administered during a patient's acute withdrawal period, with the acute withdrawal part comprising the following treatment stages:

a first phase treatment of a first stage which comprises the administration of the intravenous infusion composition to the patient to eliminate heroin/morphine from the patient's body, and administering a first supplementary composition for improving detoxification, blocking a damage path of the heroin or morphine intoxication, and activating the patient's liver to relieve neuropathic pains to the intravenous infusion composition;

a second phase treatment of the first stage continues in which the administration of the intravenous infusion composition is continued to be administered to the patient, and further comprising administering Haloperidol and Diazepam to the patient according to the level of the patient's restlessness;

a third phase treatment of the first stage wherein the intravenous infusion is continued to be administered so as to complete an acute withdrawal of heroin and morphine at percentages of up to 70% to 95%, wherein damage to the brain caused by heroin and morphine is blocked; and

a second stage of treatment wherein the intravenous infusion is continued to be administered to the patient, further comprising administering Akineton (Biperiden HCL) in the intravenous infusion, whereby the patient's consciousness recovers to what is normal for the patient.

4. The method according to claim 3 , wherein the first phase treatment of the first stage takes place within a treatment period of from the 4 hours to 18 hours and and encompasses the administration of the first dosage amount to the fifth dosage amount of the intravenous infusion composition to the patient, and with the first supplementary composition consisting of Haloperidol, Diazepam, Nefopam, and Sukerin administered into the intravenous infusion composition according to the level of patient's clinical symptoms.

5. The method according to claim 4 , wherein the first phase treatment of the first stage administers the first supplementary composition consisting of Vitamin B12, and further comprising administering a second supplementary composition consisting of Cerebrolysin and Guronsan to the patient to assist circulation and metabolism, and enhance physiological detoxication function.

6. The method according to claim 4 , wherein the second phase treatment of the first stage takes place within a treatment period of from 18 hours to 36 hours and applies the sixth dosage to the ninth dosage of the intravenous infusion composition to the patient.

7. The method according to claim 6 , wherein the third phase treatment of the first stage takes place within a treatment period of from 36 hours to 72 hours and administers the ninth dosage to the eighteenth dosage of the intravenous infusion composition to the patient.

8. The method according to claim 7 , wherein the second stage takes place within a treatment period of from the 72 hours to 96 hours.

9. The method according to claim 3 , further comprising the administration of an outpatient part which is administered during the patient's acute withdrawal period and with a standard period of 6˜12 hours, and three dosages of the intravenous infusion composition being used as a course, and the intravenous infusion composition being injected at a speed of 2˜4 hours per dosage according to a standard treatment record sheet, and with the first supplementary composition together with the intravenous infusion composition being injected by intravenous infusion according to the patient's symptoms.

10. The method according to claim 9 , wherein the outpatient part administers a second supplementary composition consisting of Nefopam and Sukerin into the intravenous infusion composition according to the patient's symptoms, and supplies Vitamin B12, Cerebrolysin and Guronsan to the patient.

11. A method for blocking heroin or morphine intoxication comprising administering the intravenous infusion composition according to claim 1 , further including the administration of an acute withdrawal part wherein said part is administered during a patient's acute withdrawal period, with the acute withdrawal part comprising the following treatment stages:

a first phase treatment of a first stage which comprises the administration of the intravenous infusion composition to the patient to eliminate heroin/morphine from the patient's body, and administering a first supplementary composition for improving detoxification, blocking a damage path of the heroin or morphine intoxication, and activating the patient's liver to relieve neuropathic pains to the intravenous infusion composition;

a second phase treatment of the first stage continues in which the administration of the intravenous infusion composition is continued to be administered to the patient, and further comprising administering Haloperidol and Diazepam to the patient according to the level of the patient's restlessness;

a third phase treatment of the first stage wherein the intravenous infusion is continued to be administered so as to complete an acute withdrawal of heroin and morphine at percentages of up to 70% to 95%, wherein damage to the brain caused by heroin and morphine is blocked; and

a second stage of treatment wherein the intravenous infusion is continued to be administered to the patient, further comprising administering Akineton (Biperiden HCL) in the intravenous infusion, whereby the patient's consciousness recovers to what is normal for the patient.

12. The method according to claim 11 , wherein the first phase treatment of the first stage takes place within a treatment period of from 4 hours to 18 hours and and encompasses the administration of the first dosage amount to the fifth dosage amount of the intravenous infusion composition to the patient, and with the first supplementary composition consisting of Haloperidol, Diazepam, Nefopam, and Sukerin administered into the intravenous infusion composition according to the level of patient's clinical symptoms.

13. The method according to claim 12 , wherein the first phase treatment of the first stage administers the first supplementary composition consisting of Vitamin B12, and further comprising administering a second supplementary composition consisting of Cerebrolysin and Guronsan to the patient to assist circulation and metabolism, and enhance physiological detoxication function.

14. The method according to claim 12 , wherein the second phase treatment of the first stage takes place within a treatment period of from 18 hours to 36 hours and applies the sixth dosage to the ninth dosage of the intravenous infusion composition to the patient.

15. The method according to claim 14 , wherein the third phase treatment of the first stage takes place within a treatment period of from 36 hours to 72 hours and administers the ninth dosage to the eighteenth dosage of the intravenous infusion composition to the patient.

16. The method according to claim 15 , wherein the second stage takes place within a treatment period of from 72 hours to 96 hours.

17. The method according to claim 11 , further comprising the administration of an outpatient part which is administered during the patient's acute withdrawal period and with a standard period of 6˜12 hours, and three dosages of the intravenous infusion composition being used as a course, and the intravenous infusion composition being injected at a speed of 2˜4 hours per dosage according to a standard treatment record sheet, and with the first supplementary composition together with the intravenous infusion composition being injected by intravenous infusion according to the patient's symptoms.

18. The method according to claim 17 , wherein the outpatient part administers a second supplementary composition consisting of Nefopam and Sukerin into the intravenous infusion composition according to the patient's symptoms, and supplies Vitamin B12, Cerebrolysin and Guronsan to the patient.

Priority Claims (1)
TW 104140659 A · Dec 4, 2015 · national
Continuity (1)
Related Publication 20170157209A1 · Jun 8, 2017